source
- Second life for gene therapy; Takeda Phase 2/3 win; UK cancer biotech's $83MA blood test might predict who will respond to Wegovy; Viridian's thyroid eye disease drug wins another Phase 3; Ideaya drops two GSK-returned assets. 🧬 Second life for a gene therapy: A Cleveland…Endpoints · 2mo ago↗ source
- Swiss manufacturing, biotech industry so far unfazed by geopoliticsBASEL, Switzerland — Pharma manufacturing in Switzerland appears to be unperturbed by the threat of tariffs, but it might take several years before the impact of companies moving production to the…Endpoints · 2mo ago↗ source
- Pfizer ends Trillium-related development as R&D spend jumpsPfizer has discontinued the final clinical study stemming from its 2021 acquisition of Trillium Therapeutics, funneling cash primarily toward a host of other cancer and obesity studies. The company…